IsoPlexis offers a highly multiplexed, fast, and fully automated workflow, using small sample volumes for same-day data and insights. Learn how in this eBook.
On the heels of a two-day FDA meeting in which experts debated the risks of gene therapy, the biotech said its early-stage PKU treatment was associated with cancer in mice.
Wall Street analysts expect little impact on biotech developers after an inconclusive discussion last week. Yet the FDA still appears wary, as shown by a new hold on a BioMarin rare disease treatment.
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen.
Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles. Learn how you can overcome them.
Highly anticipated study results showed divergent outcomes for the biotech's therapy in treating a form of vision loss known as geographic atrophy. Even so, Apellis plans to soon ask for FDA approval.
Long a bystander in the race to develop so-called allogeneic treatments, the cancer drugmaking giant has joined the fray with a wide-ranging alliance that could be worth up to $3 billion.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255 23rd Street NW, Suite 550, Washington, DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
No comments:
Post a Comment